NECA-stimulated degranulation is not prevented by pertussis toxin and is blocked by enprofylline (K i ϭ 7 M), an antiasthmatic xanthine with low affinity (K i Ͼ 100 M) for A 1 AR, A 2A AR, and A 3 AR. NECA increases canine mastocytoma cell cAMP, Ca 2ϩ , and inositol trisphosphate levels; these responses are antagonized half-maximally by 7-15 M enprofylline. The results suggest that (i) the cloned canine A 3 AR is structurally and pharmacologically more similar to human than to rat A 3 AR; (ii) the A 2B AR, and not the A 1 AR or A 3 AR, is principally responsible for adenosine-mediated degranulation of canine BR mastocytoma cells; and (iii) the BR cell A 2B AR couples to both Ca 2ϩ mobilization and cAMP accumulation. Although A 2B receptors play a major role in the regulation of BR mast cell degranulation, multiple AR subtypes and G proteins may influence mast cell functions.
Adenosine exerts numerous physiological effects that were originally thought to be mediated by three adenosine receptors, A 1 , A 2A , and A 2B . In the early 1990s, a new adenosine receptor was cloned from rat tissues, first by Meyerhof et al. (1) and then by Zhou et al. (2) , who named it A 3 . More recently, human (3), sheep (4) , and rabbit (5) (2, 4, 6) . One unusual property of A 3 adenosine receptors is a major difference among species in the binding affinity of xanthine antagonists. In particular, the rat receptor is resistant to blockade by xanthines, whereas sheep, human, and rabbit receptors bind certain xanthines with high affinity, although with distinct potency orders (3) .
The addition of adenosine to rat basophilic leukemic cells (RBL 2H3 cells; a tumor cell line resembling mast cells) causes facilitation of the release of granules, which is mediated by A 3 adenosine receptors (7, 8) . A 3 receptor activation also triggers the degranulation of mast cells surrounding hamster cheek pouch arterioles (9) . Based on these results, the observation that the inhalation of adenosine produces histamine release and bronchoconstriction in asthmatics but 125 not in nonasthmatics (10, 11) and the discovery of high levels of A 3 adenosine receptor transcript in human and sheep lung, we proposed a role for the A 3 adenosine receptor in the pathophysiology of asthma (12) . Because rodents may be poor animal models for the investigation of the role of A 3 receptors in human allergy and asthma, we decided to clone the canine A 3 adenosine receptor as a first step toward characterizing the role of A 3 adenosine receptors in canine models of asthma.
Here, we report the cloning, expression, and pharmacological characterization of an A 3 adenosine receptor cDNA isolated from BR cells [canine mastocytoma cells (13) ]. Low levels of both A 1 and A 3 adenosine receptors are found on BR cells, but these are not primarily responsible for stimulating degranulation of this canine mastocytoma cell line. Rather, an A 2B adenosine receptor causes degranulation via a pertussis toxin-insensitive pathway that mobilizes mastocytoma cell Ca 2ϩ and can be blocked by the antiasthmatic xanthine enprofylline (14) . (15) . Cell culture media and supplies were from GIBCO BRL (Gaithersburg, MD).
Experimental Procedures
Cell culture. COS-7 cells were grown in DMEM with 10% fetal calf serum, 100 units/ml penicillin, and 100 g/ml streptomycin. Canine BR mastocytoma cells were grown in low-glucose DMEM supplemented with 2% calf serum, 25 mM HEPES, 1.5 mM l-histidine, 100 units/ml penicillin G, and 100 g/ml streptomycin. The medium was changed every 3 days, and the cells were replated weekly.
Molecular cloning. To obtain the full-length sequence of the canine A 3 adenosine receptor cDNA, a library prepared in gt10 from BR cell poly(A) ϩ RNA was screened using a probe generated by RT-PCR of total RNA isolated from dog tissues using the cDNA cycle kit (InVitrogen, La Jolla, CA). Primers for amplification were primer A (sense 132-152), 5Ј-GACCACCACCTTCTATTTCA-3Ј; and primer B (antisense 660-680), 5Ј-GTCTTGAACTCCCGA/TCC-3Ј. The primers correspond to conserved regions within the first and third intracellular loops of the human, sheep, and rat A 3 adenosine receptor cDNAs. Each reaction cycle consisted of incubations at 95°for 1 min, 55°for 2 min, and 72°for 3 min with 0.02 unit/ml of Taq polymerase (Promega, Madison, WI). PCR fragments were subcloned into the TA vector (InVitrogen) and sequenced with Sequenase (United States Biochemical, Cleveland, OH) using modifications for doublestranded sequencing. One fragment from lung RNA was found to be ϳ90% identical to the human, rat, and sheep A 3 receptor transcripts. This probe was labeled with [␣-32 P]dCTP (Primit II; Stratagene, La Jolla, CA) and used to screen the BR cell cDNA library. Library screening was carried out by plaque-filter hybridization. Filters were hybridized at 65°overnight in 10% dextran sulfate, 1 M NaCl, 100 g/ml herring sperm DNA, and 1 ϫ 10 6 cpm/ml radiolabeled probe and then washed in 0.5ϫ SSC/0.5% SDS at 65°. Recombinants hybridizing to the probe were plaque-purified and reprobed. Recombinant phage DNA isolated by the plaque lysate method were digested with EcoRI and electrophoresed through a 1% agarose gel to determine the insert sizes. Several clones were identified ranging in size from 0.9 to 3 kb. One clone (cA 3 13.1), which was 1.6 kb long, was subcloned into the EcoRI site of the plasmid vector pGEM-7z(Ϫ) (Promega). Double-stranded DNA was isolated, and both strands were sequenced in full, first by using T7 and Sp6 primers to get nucleotide sequence information near the 5Ј termini, and then with a series of synthetic oligonucleotide primers derived from sequences determined previously.
Radioligand binding studies. Membranes were prepared from COS-7 cells expressing the canine A 3 receptor (cA 3 13.1) or the canine A 1 receptor (RDC7); HEK 293 cells stably expressing human, rabbit or rat A 3 adenosine receptors; or canine BR cells. The full coding region of the receptor cDNAs were subcloned into the expression vector CLDN10B and transiently expressed (60 hr) in COS cells by the DEAE-dextran method (16) or stably expressed in HEK 293 cells after transfection by the Ca 2ϩ phosphate precipitation method (17) and selection in 2 mg/ml G-418. Transfected cells were washed in phosphate-buffered saline; homogenized in 10 mM EDTA, 10 mM Na-HEPES, pH 7.4, and 0.1 mM benzamidine; and centrifuged at 20,000 ϫ g for 20 min. Pellets were resuspended and washed in 10 mM Na-HEPES, 1 mM EDTA, pH 7.4, and 0.1 mM benzamidine (HE buffer) and resuspended in the same buffer with 10% (w/v) sucrose (sucrose buffer) at a membrane protein concentration of 1 mg/ml. Because [
125 I]ABA bound poorly to crude BR cell membranes, plasma membranes were enriched by preparing P2 pellets. Cells were homogenized in sucrose buffer and centrifuged at 500 ϫ g for 10 min. The pellet was resuspended in sucrose buffer and centrifuged again at 500 ϫ g. The pooled supernatants were diluted 3-fold, pelleted, and washed twice by centrifugation at 20,000 ϫ g for 20 min in HE buffer; resuspended; and frozen in sucrose buffer. Protein concentrations were determined using fluorescamine with BSA as standard. Membranes were frozen in aliquots and stored at Ϫ80°. For radioligand binding studies, cell membranes were incubated in 0.1 ml for 3 hr at 21°with 5 mM MgCl 2 and 5 units/ml adenosine deaminase. For equilibrium binding assays, [6] [7] [8] 
Optimal parameters for two-site Scatchard plots were generated by using the , is complicated by the fact that both the radioligand the competing compounds bind to two affinity states. This is described by four equations:
where LB is radioligand bound, CB is competitor bound, L is free radioligand, C is free competitor, and f is fraction of L or C nonspecifically bound (assumed to be equal). K d1 , K d2 , and the fraction of coupled receptors were derived from equilibrium radioligand binding in the absence of competitor. The other parameters were determined by simultaneously solving these four equations by interpolation within each iteration of nonlinear least-squares analysis. For the analysis of antagonist binding, K i1 and K i2 values were set to be equal based on the assumption that antagonists bind with similar affinities to G protein-coupled and -uncoupled receptors.
Northern blots. Northern analysis and RT-PCR were used to determine the tissue distribution of A 3 adenosine receptor transcript and to identify A 2B , A 1 , and A 3 receptor transcripts in BR cells. Total RNA was extracted and poly(A) ϩ RNA was selected using oligo(dt) cellulose. Five micrograms of poly(A) ϩ RNA was electrophoresed through 1% agarose gels containing 1% formaldehyde and then transferred to nylon membranes (Genescreen Plus; DuPont). The membranes were hybridized in 10% dextran sulfate, 1 M NaCl, and 100 g/ml herring sperm DNA with 1 ϫ 10 6 cpm/ml random-labeled probe at 65°overnight. Filters were washed with 0.5ϫ SSC/0.5% SDS at 65°and then exposed to Amersham Hyperfilm MP for 24-48 hr. The A 3 receptor probe consisted of a 600-bp PCR fragment of cA 3 13.1, corresponding to approximately half of the carboxyl-terminal sequence and the 3Ј noncoding region. The A 2B receptor probe consisted of a 500-bp PCR fragment generated by RT-PCR from BR cell RNA corresponding to transmembrane regions I-IV.
For RT-PCR, 1 g of poly(A) ϩ -selected RNA was reverse-transcribed and amplified using primers A and B described above. The reactions were electrophoresed and transferred to nylon membranes (Hybond N ϩ ; Amersham) using denaturing buffer (0.4 N NaOH) and hybridized with specific probe. Filters were washed under stringent conditions (0.1ϫ SSC/0.5% SDS at 65°for 1 hr). Control reactions were included in which RT or RNA was excluded from the reactions. Some of the PCR fragments were subcloned into the TA vector and partially sequenced.
Mastocytoma cell degranulation. As an indicator of degranulation of BR cells, we measured the release of ␤-hexosaminidase (a granule-associated protein that parallels histamine release) using a modification of the method of Schwartz et al. (20) . BR cells grown in suspension were washed twice in Ca 2ϩ /Mg 2ϩ -free Tyrode's buffer and then resuspended in complete Tyrode's at a density of 1.2 ϫ 10 6 cells/ml. Cells were then transferred to a 96-well plate in 250-l aliquots and prewarmed to 37°for 15 min. Cells were stimulated with agonists added in 50-l aliquots for 20 min at 37°with shaking. The reactions were stopped by placing the plate on ice for 10 min and then pelleting the cells by centrifugation at 200 ϫ g for 10 min (4°). Two hundred microliters of the supernatant was removed and added to 50 l of 5 mM p-nitrophenyl-N-acetyl-D-glucosaminide, and 100 mM citric acid, pH 3.8, and incubated at 37°for 2 hr with shaking before the addition of 50 l of 0.4 M NaCO 3 . Total cellular ␤-hexosaminidase was determined by adding 50 l of lysis buffer (complete Tyrode's buffer plus 0.6% Triton A-100) to 250-l aliquots of cells, and 20 l was removed and assayed. Absorbance was read at 405 nm using a Titertech Multiskan II plate reader. Experiments were performed in triplicate, and release of ␤-hexosaminidase is expressed as percentage of the total content of unstimulated cells.
cAMP. BR cells were washed twice and resuspended in serumfree low-glucose DMEM containing 25 mM HEPES, 1 unit/ml adenosine deaminase, and 20 M Ro 20-1724 and then transferred to polypropylene test tubes (1 ϫ 10 6 cells/0.2 ml, 21°). Drugs were added in 50-l aliquots, and the tubes were placed in a 37°shaking water bath for 20 min. Assays were terminated by the addition of 500 l of 0.15 N HCl. cAMP in the acid extract (500 l) was acetylated and quantified by automated radioimmunoassay.
Intracellular Ca 2؉ . BR cells were loaded with 1 M Fura-2/AM in buffer containing 100 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 1 mM KH 2 PO 4 , 25 mM NaHCO 3 , 0.5 mM CaCl 2 , 2.7 g/liter D-glucose, 20 mM Na-HEPES, pH 7.4, and 0.25% BSA for 45 min. Cells were washed and resuspended in the same buffer without BSA, plus 1 unit/ml adenosine deaminase to a density of 1 ϫ 10 6 cells/ml. Fluorescence was measured with an SLM spectrofluorimeter in a thermostable cuvette (37°).
InsP 3 . BR cells were preincubated for 24 hr with 2.5 Ci/ml myo-[ 3 H]inositol in inositol-free low-glucose DMEM supplemented with 2% dialyzed fetal calf serum. The labeled cells were washed and resuspended in low-glucose DMEM with 25 mM HEPES, 1 unit/ml adenosine deaminase, and 100 mM LiCl and then transferred to polypropylene test tubes (4 ϫ 10 5 cells/0.2 ml) at 37°in a shaking water bath and stimulated by 5ϫ agonists added in 50-l aliquots for 10 min. Assays were terminated by the addition of 400 l stop solution (0.5 M HCLO 4 , 5 mM EDTA, and 1 mM diethylenetriaminpentacetic acid) plus 1 mg/ml phytic acid and placed on ice for 30 min before the addition of 5 M K 2 CO 3 to raise the pH to 8-9. After centrifugation, the supernatants were passed through a 0.2-m filter, applied to 1-ml Dowex AG 1-X8 columns (200-400 mesh), and washed with 5 ml of H 2 O and 5 ml of 40 mM HCl; then, InsP 3 was eluted with 5 ml of 170 mM HCl.
Results
Molecular cloning of the canine A 3 adenosine receptor. The screening of a canine mastocytoma cDNA library with an A 3 adenosine receptor probe generated by RT-PCR resulted in the identification of several positively hybridizing clones. A clone designated cA 3 13.1 contains a 1.6-kb insert with an open reading frame corresponding to 314 amino acids and 181 and 480 bp of 5Ј and 3Ј untranslated sequence, respectively ( Fig. 1) . A hydrophilicity plot of the deduced amino acid sequence predicts seven transmembrane domains, which are indicated in Fig. 2A . Sites found to be conserved within all species of A 3 adenosine receptors cloned to date include a putative palmitoylation site at Cys305 of the consensus sequence and two putative N-linked glycosylation sites at Asn4 and Asn162. Several putative phosphorylation sites are conserved among the A 3 adenosine receptors, including four potential sites for phosphorylation by protein kinase C (Thr124, Thr125, Ser/Thr215, and Thr230); one potential site for phosphorylation by tyrosine kinases (Tyr120); and one potential site for phosphorylation by cAMP/cGMP-dependent protein kinases (Thr294). The carboxyl tail distal to the palmitoylation site contains several serine/threonine residues that are surrounded by acidic groups that may be sites for phosphorylation by G protein receptor kinases.
The deduced amino acid sequence of cA 3 13.1 is 88%, 86%, 72%, and 77% identical to the human, sheep, rat, and rabbit receptors (Fig. 2B) , respectively, and 52% and 47% identical to canine A 1 and A 2A receptors, suggesting that cA 3 13.1 is the canine species homolog of the A 3 adenosine receptor. Be- tween species, the greatest degree of homology lies within the transmembrane domains, and the least lies within the carboxyl tail. Of the five species of A 3 adenosine receptors cloned to date, the human receptor amino acid sequence is most similar to the canine and least similar to the rat. We noted previously that the human and rat A 3 adenosine receptors are unusually divergent for species homologs (12) . In contrast, canine and human A 3 adenosine receptors show a degree of amino acid sequence homology that is similar to species differences among the other adenosine receptor subtypes (Fig. 2B) .
Tissue distribution of A 3 mRNA. Northern blots probing for cA 3 13.1 transcripts in several different canine tissues revealed two hybridizing bands of 1.9 and 2.7 kb (Fig. 3 ). Transcripts were most abundantly expressed in spleen, but high levels also were detected in lung and liver. Two major hybridizing bands were also observed in testes, but the sizes were 1.3 and 2.4 kb. Transcripts were not detected in heart or kidney by Northern analysis. Using the sensitive technique of RT-PCR, trace transcripts were observed in all six tissues studied (data not show). 3 13.1 (Fig. 4) . Specific binding was absent in untransfected cells and was abolished by 1 M nonradioactive I-ABA. NEthylmaleimide has been reported to alkylate G proteins in the G i/o family and cause them to become uncoupled from receptors. GTP␥S and N-ethylmaleimide both reduced specific binding of [
125 I]ABA to canine A 3 adenosine receptors by ϳ60%, indicating that the radioligand is an agonist and that G i /G o proteins couple to the A 3 receptor (Fig. 4A) . In equilibrium binding studies, [
125 I]ABA specific binding was consistently found to fit significantly ( p Ͻ 0.01) better to a two-site than to a one-site model (22 (Fig. 4C) . These results suggest that the high affinity site reflects binding to G protein-coupled receptors and the low affinity site reflects binding to uncoupled receptors. A similar analysis indicates that [ We next compared the binding properties of recombinant canine A 1 and A 3 adenosine receptors. Fig. 6 shows the results of competition binding studies with compounds found to be the most A 3 selective, IB-MECA and I-ABOPX, and those most A 1 selective, CPA and WRC-0571. K i values of these and other compounds are summarized in Tables 1 and  2 . These tables also summarize the relative affinities of competing compounds for canine A 1 and A 3 receptors. For the A 3 receptor subtype, two dissociation constants for agonists and single dissociation constants for antagonists were calculated as described in Experimental Procedures. The potency order of agonists for canine A 3 receptors was IB-MECA Ն (Table 2 ). Theophylline and enprofylline bind very weakly to canine A 3 adenosine receptors; a 100 M concentration of these compounds reduces specific binding by only ϳ40%. I-ABOPX is 16-fold selective for canine A 3 over A 1 adenosine receptors. Table 3 shows a comparison of the binding affinities of four Little specific binding could be detected to crude membranes, but the binding of 0.4 nM radioligand to an enriched P2 membrane preparation was 80% specific (Fig. 7) . Of the [ 125 I]ABA binding site on BR cell membranes, 24 Ϯ 3% (three experiments) bind WRC-0571 with low affinity (IC 50 ϭ 22 Ϯ 9 M) characteristic of A 3 receptors; the remainder bind WRC-0571 with high affinity (IC 50 ϭ 114 Ϯ 38 nM) characteristic of A 1 receptors (Fig. 7, Table 2 ). When added at 0.4 nM, [
125 I]ABA labeled only 2.4 fmol/mg of protein of A 3 receptors in the P2 membranes of BR cells, suggesting the density of A 3 receptors on BR cells is low.
Characterization of the adenosine receptor that causes degranulation of canine mastocytoma cells. Adenosine agonists have been shown to enhance A23187 (calcimycin)-stimulated degranulation of several types of mast cells, including murine bone marrow-derived mast cells, human lung mast cells, RBL-2H3 cells, and rat peritoneal mast cells (23, 24) . Fig. 8 shows the effect of increasing concentrations of Ca 2ϩ ionophore to elicit ␤-hexosaminidase release from BR cells when administered alone or in combination with the nonselective adenosine receptor agonist NECA (10 M). When administered alone, A23187 evokes a maximal release of ϳ15.6% of the total cellular content after Table 1. 20 min of stimulation. NECA (10 M) alone also stimulates ␤-hexosaminidase release (5.81 Ϯ 0.59%), and costimulation with NECA and A23187 increases ␤-hexosaminidase release to 28.2 Ϯ 1.8%. NECA decreases the EC 50 for A23187 from 0.32 Ϯ 0.06 to 0.13 Ϯ 0.08 M.
We next conducted experiments to determine whether NECA acts at receptor sites on the cell surface or at intracellular sites. To test the possibility that NECA may gain access into BR cells via facilitated uptake and influence the degranulation response via an intracellular mechanism, BR cells were preincubated for 15 min with NBTI (1 M), an inhibitor of nucleoside transport. As shown in Fig. 8B , NBTI did not influence the concentration response of NECA to stimulate ␤-hexosaminidase release. As additional evidence that NECA acts at cell surface adenosine receptors, we added XAC, a nonselective antagonist of all subtypes of canine adenosine receptors, including A 3 (see Table 2 ). XAC completely abolished the stimulatory effect of NECA (Fig. 8B) . Additional experiments were performed with NBTI and XAC during costimulation with a combination of A23187 and NECA. As in the absence of A23187, NBTI had no effect, and XAC abolished NECA-mediated degranulation responses (data not shown).
Pertussis toxin blocks the inhibition of cAMP accumulation in CHO-K1 cells that is mediated by recombinant rat A 3 adenosine receptors (2) . Pertussis intoxication of rats also reduces a putative A 3 adenosine receptor-mediated hypotensive response (25) . These data suggest that A 3 adenosine receptors functionally couple to G i /G o proteins; therefore, we examined the effect of pretreating BR cells with pertussis toxin on the ability of NECA to stimulate degranulation (Fig.  9 ). For these experiments, BR cells were cultured in serumfree medium with 0.3 or 1 g/ml of pertussis toxin for 24 hr. 1 We found that cells cultured in serum-free medium released a greater amount of ␤-hexosaminidase in response to 1 M A23187 (ϳ25-35% without serum versus ϳ15% with serum). Pretreatment of cells with either concentration of pertussis toxin did not prevent NECA-stimulated degranulation. These data suggest that neither A 1 nor A 3 adenosine receptors are solely responsible for adenosine-mediated degranulation of BR cells.
We next determined the potency order of various adenosine analogs to stimulate ␤-hexosaminidase release from BR cells. In addition to NECA, we examined (R)-PIA (A 1 selective), CGS 21680 (A 2A selective), and IB-MECA (A 3 selective). Experiments were performed in the presence or absence of 1 M A23187 (results are illustrated in Fig. 10 and summarized in Table 4 ). The potency order of agonists to stimulate canine mast cell degranulation, NECA Ͼ PIA Ͼ CGS-21680 Ͼ IB-MECA, differs from the potency order of these compounds for binding to canine A 3 adenosine receptors, IB-MECA Ͼ PIA Ͼ NECA Ͼ CGS-21680. IB-MECA has very little stimulatory effect on BR cell degranulation and, when added at 10 M, IB-MECA inhibits degranulation.
The observed potency order for adenosine analogs to stimulate BR mast degranulation is similar to the potency order reported by Brackett and Daly (26) for activating A 2B receptors on NIH 3T3 fibroblasts and the potency order for binding to recombinant human A 2B receptors (27) . Furthermore, A 2B receptors in general have low affinity for agonists, similar to their low affinity for stimulating degranulation of BR cells 1 Serum-free medium was used to avoid the potential for neutralization of pertussis toxin by anti-toxin antibodies that exist within some lots of serum. (Table 4) . Because A 2B receptor transcript is found in BR cells, we postulated that A 2B adenosine receptors are expressed on BR cells and, when activated, stimulate degranulation. To test this hypothesis, we investigated the effects of enprofylline, which we recently identified as a selective antagonist of recombinant human A 2B receptors (27) . Concentration-response curves for degranulation in response to NECA were generated in the presence of 10, 50, and 250 M enprofylline. As shown in Fig. 11A , increasing concentrations of enprofylline produced parallel rightward shifts of the concentration-response curves for ␤-hexosaminidase release. Schild regression analysis revealed a slope close to unity (1.12 Ϯ 0.45), suggesting that enprofylline acts as a competitive antagonist at a single receptor subtype. The K D value of enprofylline was estimated to be 7.8 Ϯ 3.3 M. This value is almost identical to the K I value of enprofylline for binding to human A 2B receptors and is well below the K I value of enprofylline for canine A 1 or A 3 receptors. Interestingly, the K i value of enprofylline for A 2B receptors lies within the therapeutic range of this compound as an antiasthmatic therapeutic agent (28) . Because enprofylline also inhibits cAMP phosphodiesterase, we evaluated the effects of another phosphodiesterase inhibitor, Ro 20-1724, on NECA-induced ␤-hexosaminidase release. Ro 20-1724 is a nonxanthine that does not bind to adenosine receptors. As shown in Fig. 11B , Ro 20-1724 has no effect on NECA-induced degranulation. The data are consistent with the possibility that enprofylline blocks BR cell degranulation by binding to A 2B adenosine receptors.
Second messenger responses evoked by A 2B receptor activation in canine mastocytoma cells. We next measured second messenger responses to adenosine receptor activation in BR cells. Unlike A 3 adenosine receptors, which are inhibitory to adenylyl cyclase, A 2B adenosine receptors stimulate adenylyl cyclase (26) . We measured changes in intracellular levels of cAMP, Ca 2ϩ , and InsP 3 in response to NECA, CGS 21680, and IB-MECA. As shown in Fig. 12 , NECA, but not CGS 21680 or IB-MECA, produces a concentration-dependent increase in intracellular levels of cAMP. The absence of cAMP accumulation in response to CGS-21680 indicates that accumulation of the cyclic nucleotide in response to NECA is not mediated by A 2A adenosine receptors. The calculated EC 50 for NECA to increase cAMP in BR cells is 0.9 Ϯ 0.2 M, which is similar to the EC 50 value for NECA to stimulate ␤-hexosaminidase release (0.6 Ϯ 0.3 M), suggesting that both responses are mediated by the same receptor subtype. NECA (1 M) also increased intracellular levels of Ca 2ϩ and InsP 3 , whereas 1 M CGS -21680 or 1 M IB-MECA had little effect (Fig. 12) . Small responses to CGS 21680 and IB-MECA to influence cAMP, Ca 2ϩ , or InsP 3 suggest that selective activation of A 2A or A 3 receptors has little effect on cAMP or Ca 2ϩ signaling in canine BR mastocytoma cells.
Enprofylline competitively antagonized the increases in intracellular levels of cAMP and Ca 2ϩ produced by NECA (Fig. 13) . By Schild regression analysis (slope ϭ 0.81 Ϯ 0.15), the K D value of enprofylline was estimated to be 4.7 Ϯ 3.2 M from the cAMP response and 15 M from the Ca 2ϩ response, values similar to the K D value estimated for enprofylline to inhibit NECA-stimulated ␤-hexosaminidase release (7.8 M). These results suggest that A 2B receptors in BR cells are positively coupled to adenylyl cyclase and phospholipase C.
Discussion
We cloned and characterized a canine A 3 adenosine receptor cDNA designated cA 3 13.1 from canine BR mastocytoma cells. The clone is homologous to A 3 receptors cloned from other species. Transcripts for A 1 and A 2B adenosine receptors also were detected in BR cells, and evidence of A 1 , A 2B , and A 3 receptor expression was found on the basis of radioligand binding or functional assays. The A 2B receptor predominates in the regulation of BR cell degranulation, as discussed in detail below.
The tissue distribution of A 3 adenosine receptor transcript in dog is similar to the human distribution (3), with highest levels expressed in spleen, followed by lung and liver. The tissue distribution is different from rat, in which transcript is much more abundant in testes than in other tissues (1) . In terms of sequence homology and pharmacology, the canine A 3 adenosine receptor is more similar to the human than to the rat A 3 receptor.
The results of radioligand binding assays with the A 1 /A 3 agonist [ Table  1 , I-ABA and IB-MECA both bind with high affinity (K D Ͻ 1 nM) to the G protein-coupled conformation of canine A 3 receptors. Failure to analytically resolve the two agonist affinity states in radioligand binding assays will result in underestimation of high affinity agonist dissociation constants as well as errors in the calculation of the dissociation constants of competing compounds based on the Cheng and Prusoff formula (30) . It is notable that in the range of 0.1-1 M, compounds that often are used as selective agonists of A 1 receptors (CPA) or A 2A receptors (CGS-21680) also will bind to canine A 3 receptors. Hence, caution must be taken in attributing functional responses of these compounds to particular adenosine receptor subtypes.
This study confirms and extends the observation that there are substantial species differences in the binding of xanthines to A 3 adenosine receptors. The rat A 3 adenosine receptor, the first A 3 adenosine receptor to be cloned, was originally reported not to bind xanthine antagonists (2) . Subsequent studies have shown that xanthines bind weakly to the rat receptor. The most potent xanthine antagonist, I-ABOPX, binds to the rat A 3 receptor with a K I value of 1.5 M. In contrast, sheep, human, and canine A 3 receptors bind I-ABOPX with 80 -500 times higher affinity (3, 4) .
CPX is widely regarded as a selective antagonist of A 1 adenosine receptors. Although CPX is Ͼ250-fold selective for human A 1 over A 3 receptors (27) , this selectivity drops to only 10-fold in the case of canine receptors. This is partly due to the fact that compared with human and sheep A 3 receptors, canine A 3 receptors bind CPX with relatively high affinity. In addition, canine A 1 adenosine receptors have lower affinity than other species for CPX. Consequently, CPX is not particularly useful for discriminating between A 1 and A 3 receptormediated responses in the dog. A preferable compound for this purpose is WRC-0571, an A 1 -selective nonxanthine antagonist that is Ͼ4000-fold selective for human A 1 over A 3 receptors (31). Although WRC-0571 binds with much lower which is sometimes used as a A 3 receptor antagonist on the basis of its moderate affinity for sheep and human A 3 receptors (3, 4) . BW-A1433 is a relatively weak and nonselective antagonist of canine A 3 receptors, binding with 10-fold lower affinity to canine than to human A 3 receptors.
Enprofylline, an antiasthmatic agent that has moderate affinity for human A 3 receptors [K I ϭ 156 Ϯ 110 M (27)], binds poorly to the canine A 1 and A 3 receptors (K I Ͼ 100 M). Because enprofylline binds to the human A 2B adenosine receptors with a K I value of 7 M (27), the compound was evaluated in this study to discriminate between canine A 2B and A 1 or A 3 adenosine receptor-mediated responses. Inasmuch as the canine A 3 receptor clone was isolated from a canine mastocytoma cDNA library, we anticipated that the A 3 receptor subtype would be responsible for stimulating the release of granule-associated mediators. However, A 2B and A 1 as well as A 3 transcript were found in BR cells, and low levels of A 1 and A 3 receptor binding sites could be detected on enriched plasma membranes prepared from the canine mastocytoma cells. Nevertheless, several lines of evidence indicate that BR cell degranulation requires activation of the A 2B but not the A 1 or A 3 adenosine receptor: (i) degranulation of BR cells is not prevented by pretreatment of cells with per- -mobilizing G protein resistant to pertussis toxin (G q/11 ) may be essential for triggering BR cell degranulation because agents that elevate cAMP in various kinds of mast cells, including agonists of A 2A adenosine receptors, either have no effect or are inhibitory to degranulation (34, 35) .
The conclusions of previous studies have been inconsistent regarding the adenosine receptor subtype that mediates mast cell degranulation. Recent DNA antisense experiments suggest that activation of A 1 adenosine receptors may contribute to bronchoconstriction in a rabbit model of asthma (36) . However, the low potency of various A 1 -selective xanthines to block histamine release from asthmatic human lung fragments (10) and the low potency of enprofylline to block human A 1 adenosine receptors (27) are consistent with the participation of A 2B and/or A 3 receptors in human disease. The A 3 adenosine receptor has been implicated in the degranulation of RBL 2H3 rat mast cells and in triggering vascular responses 3 secondary to degranulation of mast cells in the hamster cheek pouch (9, 37) and the pithed rat (25) . A 2B adenosine receptors seem to mediate the degranulation of murine bone marrow-derived mast cells (21) , and although pretreatment of RBL 2H3 rat mast cells with pertussis toxin abolishes NECA-mediated degranulation, Ca 2ϩ mobilization in these cells requires activation of G i3 or G q (38) . Moreover, activation of phosphoinositide breakdown in RBL 2H3 cells is not well correlated with the affinity of adenosine analogs for A 3 adenosine receptors (39) . The treatment of murine bone marrow mast cells with pertussis toxin produces a decrease in the potency of adenosine to enhance degranulation in response to A23187, similar to the result in the current study with canine mastocytoma cells. Pretreatment of murine mast cells with pertussis toxin fails to reduce adenosine-mediated Ca 2ϩ mobilization, which is consistent with an A 2B -mediated, but not an A 3 -mediated, response (40) . In the human HMC-1 mast cell leukemia line, the ability of 300 M enprofylline to block NECA-stimulated interleukin-8 release was taken as evidence that this response also is mediated by A 2B adenosine receptors (41) . The current study tends to substantiate previously published reports that suggest the receptor subtype primarily responsible for adenosine-mediated mast cell degranulation is variable. It is not yet clear whether this variability depends on species, tissue source, or environmental factors that affect signaling cascades and/or the phenotype of various mast cells. The results of this study indicate that A 2B receptors play a major role in the regulation of mast cell degranulation but are consistent with possible participation of multiple adenosine receptor subtypes and multiple G proteins.
The canine A 3 adenosine receptor described in this study is structurally and pharmacologically more similar to human A 3 receptors than are A 3 receptors from rodent species. This finding, along with the fact that it seems that murine bone marrow mast cells, canine mastocytoma, and human HMC-1 leukemic mast cells are regulated by adenosine, primarily via A 2B receptors, raises the possibility that canine models of asthma may be better predictors of human disease than rodent models. It will be important to determine which adenosine receptor subtype or subtypes are responsible for facilitating mast cell degranulation in the asthmatic human lung. Once the predominant receptor or receptors are identified, novel antagonists superior to theophylline and enprofylline for the treatment of asthma may be developed. 
